New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, “significantly reduced” breast tissue cell growth, which is a major indicator of cancer ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

Pfizer offers a dividend yield over 7%, but it's payout probably won't rise very fast in the decade ahead. Investors seeking ...

Final Written Decisions in Pfizer’s IPR2021-00925 and IPR2021-00926 finding all challenged claims of uniQure’s U.S. Patent No. 9,982,248 (“the ’248 patent”) unpatentable (CAFC 23-1404 and 23-1405), ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

A new partnership between Hartford HealthCare and Pfizer is taking aim at migraines in the workplace. The innovative program ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...